X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Lung Cancer Clinical Trial

Official title:

Phase II, Open-Label, Single Arm Study of the Efficacy and Safety of X-396 Capsule in Patients With ROS1 Positive Advanced NSCLC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03608007
• Other study ID #: BTP-42723
• Status: Recruiting
• Phase: Phase 2
• Start date: June 15, 2018
• Est. completion date: September 2020

Study information

• Verified date: December 2019
• Source: Betta Pharmaceuticals Co., Ltd.
• Contact: Jinxiao Xu
• Phone: 86-18610155290
• Email: jinxiao.xu[@]bettapharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1) positive gene mutation (translocation or inversion).

Description:

This is a phase II, multicenter, single-arm study in which the efficacy and safety of X-396 capsule (Ensartinib) will be assessed in adult Chinese patients with ROS1-positive (rearrangement or inversion) non-small cell lung cancer (NSCLC). Approximately 69 patients (59 for never-treated, and 10 for previously treated with crizotinib) with locally advanced or metastatic NSCLC carrying ROS1-rearrangement will be enrolled in the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 69
• Est. completion date: September 2020
• Est. primary completion date: March 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female or male, 18 years of age or older

• Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic

• Positive for translocation or inversion events involving the ROS1 gene

• Tyrosine kinase inhibitor (TKI) treatment-naive or have previously received no more than one systemic treatment regimen(s) such as chemotherapy (After a 3-week washout period)

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

• Predicted survival = 3 months

• Drug related toxicities were relieved to grade 1, except for hair loss (based on NCI CTCAE v4.03)

• Adequate organ function

• At least 1 measurable tumor lesion as per RECIST v1.1

• Asymptomatic central nervous system (CNS) metastases do not require the use of steroids or anticonvulsants.

• Signed and dated informed consent

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

• Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment

Exclusion Criteria:

• Current treatment on another systemic anti-cancer therapy

• Prior therapy specifically directed against ROS1 fusion genes (except for the exploratory arm that will enroll patients pretreated with crizotinib)

• Evidence of active malignancy within last 3 years

• Previous therapeutic clinical trial must have completed at least 4 week prior to initiation of study drug

• Prior surgery or immunotherapy must have completed at least 4 weeks, and radiation must have been completed at least 2 weeks prior to initiation of study drug

• Known interstitial fibrosis or interstitial lung disease

• Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medication

• Clinically significant cardiovascular disease

• Patients with a known allergy or delayed hypersensitivity reaction to study drug or its excipient

• Pregnant or breast feeding

• Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers

• Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol

• Other serious illness or medical condition potentially interfering with the study

Related Conditions & MeSH terms

• Lung Cancer
• ROS1 Gene Rearrangement

Intervention

Drug:
• X-396 Capsule
225 mg once daily

Locations

Country	Name	City	State
China	Chest hospital affiliated to Shanghai jiao tong university	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Betta Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR) based on independent radiology review (IRC) according to RECIST 1.1	ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on IRC.	12 weeks
Secondary	ORR based on investigator assessment according to RECIST 1.1	ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as CR or PR, based on investigator's assessment	12 weeks
Secondary	Disease control rate (DCR) according to RECIST 1.1	DCR defined as the percentage of patients who have achieved CR, PR and stable disease (SD), based on RECIST 1.1 measured by IRC or investigator	12 weeks
Secondary	Intracranial overall response rate (iORR) by IRC and investigator assessment according to RECIST 1.1	iORR calculated as the ORR (CR+PR) of lesions in the brain for patients who have measurable disease in the brain at baseline.	12 weeks
Secondary	Progression-free survival (PFS) based on IRC or investigator according to RECIST 1.1	PFS defined as time from first dose of X-396 capsule to disease progression or death due to any cause, based on RECIST 1.1.	36 months
Secondary	Time to progression (TTP) based on IRC or investigator according to RECIST 1.1	TTP defined as time from first dose of X-396 capsule to disease progression, based on RECIST 1.1.	36 months
Secondary	Duration of response (DOR) based on IRC or investigator according to RECIST 1.1	DOR defined as time from documentation of tumor response (CR or PR) to disease progression or death, based on RECIST 1.1	36 months
Secondary	Overall survival (OS)	OS, defined as time from first dose of X-396 to death due to any cause.	36 months
Secondary	Change From Baseline Scores on the functional assessment of cancer therapy - Lung (FACT-L) quality of life questionnaire	The FACT-L questionnaire consisted of several major aspects of life (Physical, social/family, emotional, and functional well-being) as well as lung cancer subscale (symptoms, cognitive function, regret of smoking). Scores for item ranging from 0 (not at all) to 4 (very much).	36 months
Secondary	Incidence of patients experiencing adverse events (AE)	Adverse events are graded according to CTCAE 4.03	36 months